Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMVWHTG)

Drug Name

Afamelanotide Drug Info

Synonyms

[Nle4,dPhe7]alpha-MSH; alpha-NDP-MSH; NDP-MSH

Indication

Disease Entry	ICD 11	Status	REF
Erythropoietic porphyrias	5C58.12	Approved	[1]
Erythropoietic protoporphyria	5C58.12	Approved	[2]
Vitiligo	ED63.0	Phase 2	[3]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Melanocortin receptor 1 (MC1R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Bremelanotide	DM20LIM	Hypoactive sexual desire dysfunction	HA00	Approved	[4]
Dersimelagon	DMMO0SU	Erythropoietic protoporphyria	5C58.12	Phase 3	[5]
PL8177	DML5V22	Ulcerative colitis	DD71	Phase 2	[6]
AP-1030	DMBGA35	Metabolic disorder	5C50-5D2Z	Phase 1/2	[7]
MT-II	DMKT1DA	Female sexual arousal dysfunction	HA01.1	Investigative	[8]
C[Nle-Arg-D-Nal(2')-Arg-Trp-Glu]-NH2	DMX7IVO	Discovery agent	N.A.	Investigative	[9]
Ac-YRMEHdFRWG-NH2	DMN2UKC	Discovery agent	N.A.	Investigative	[10]
C[Nle-Gln-D-Nal(2')-Arg-Trp-Glu]-NH2	DMM19SJ	Discovery agent	N.A.	Investigative	[9]
C[Nle-Val-D-Nal(2')-Arg-Trp-Glu]-NH2	DMSIGJW	Discovery agent	N.A.	Investigative	[9]
C[Nle-Arg-D-Phe-Arg-Trp-Glu]-NH2	DMUESCH	Discovery agent	N.A.	Investigative	[9]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
2	Afamelanotide FDA Label
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
5	Dersimelagon, a novel oral melanocortin 1 receptor agonist, demonstrates disease-modifying effects in preclinical models of systemic sclerosis. Arthritis Res Ther. 2022 Sep 1;24(1):210.
6	Pharmacokinetics of the Melanocortin Type 1 Receptor Agonist PL8177 After Subcutaneous Administration. Drugs R D. 2021 Dec;21(4):431-443.
7	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
8	Design of potent linear alpha-melanotropin 4-10 analogues modified in positions 5 and 10. J Med Chem. 1989 Jan;32(1):174-9.
9	Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52.
10	Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8.